Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk of Cancer in Patients Exposed to Gabapentin in the GPRD

NCT01236053 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01236053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01236053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk of Cancer in Patients Exposed to Gabapentin in the GPRD
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
June 30, 2010
Completion date
September 30, 2010
Enrollment
2,323,608 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, bladder cancer, bone and joint cancer, breast cancer, cancer, chronic pancreatitis, diabetes, epilepsy, nervous system cancer, pain, neuropathic, pancreatic cancer, penis cancer, renal cancer, renal cell carcinoma, renal pelvis cancer, stomach cancer